CD8A and neoplasm: In conclusion, in addition to its direct anti-tumor effects, copanlisib modulates the intratumoral T cell compartment in a favorable way, inhibiting Tregs and promoting activated cytotoxic CD8+ T cells, which exert a strong anti-tumor immunity.